Mostrando 9 resultados de: 9
Subtipo de publicación
Article(9)
Publisher
Breast Cancer: Basic and Clinical Research(2)
BJGP Open(1)
Cancer Management and Research(1)
Clinical Cancer Research(1)
Clinical and Translational Immunology(1)
Área temáticas
Enfermedades(8)
Farmacología y terapéutica(6)
Medicina y salud(3)
Microorganismos, hongos y algas(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Origen
scopus(9)
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusEffect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
ArticleAbstract: NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target forPalabras claves:Clinical trial, Ganglioside, melanoma, N-glycolyl GM3, Therapeutic vaccineAutores:Ávila Y., Carmen Elena Viada, Carr A., Cepeda M., De La Torre A.V., Fernandez L.E., Gracia E., Hernandez J., Osorio M., Pérez K., Reigosa E., Rodríguez M., Saurez G.Fuentes:scopusMulticentre oncology clinical trials in primary health care in Cuba: evaluation of programme implementation in Villa Clara Province, 2010–2020
ArticleAbstract: Background: The Center of Molecular Immunology of Cuba has developed a programme for the conductingPalabras claves:clinical trials, General practitioners, immunotherapy, neoplasms, Oncology, Primary Health Care, primary healthcareAutores:Artiles M., Cepeda M., Crespo J.C., de la Barca N.d.C., González A., Granela M.C., Lage Davila A., Lorenzo G., Marrero R., Méndez R., Nieto L., Norvel M., Ortiz R.A., Rodríguez M., Sánchez L., Tania Crombet, Toledo E., Torres O.Fuentes:scopusNGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: Results of phase I/IIa clinical trial
ArticleAbstract: Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression frPalabras claves:Clinical trial, Ganglioside, Metastatic breast cancer, NGcGM3, Therapeutic vaccineAutores:Arboláez M., Car A., Carmen Elena Viada, Cepeda M., De La Torre A.V., Fernandez L.E., García E., Guerra P.P., Hernandez J., Ortiz R.A., Pérez K., Toledo D.Fuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusUse of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
ArticleAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreaPalabras claves:Autores:Caballero A., Calderón N.A., Cepeda M., Diáz Y., Estevez D., Hidalgo C.J., La O Y., Leon K., Lorenzo G., Luaces P.L.o., Martín Y., Mazorra Z., Oyarzábal J.P.A., Pérez Y., Ramos-Suzarte M., Saavedra Hernández D., Santiago W., Tania Crombet, Valenzuela-Silva C.M., Viñet O.Fuentes:scopusSuperior efficacy and safety of a nonemulsive variant of the NGcGM3/VSSP vaccine in advanced breast cancer patients
ArticleAbstract: NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vacPalabras claves:Breast Cancer, NGcGM3/VSSP vaccine, SurvivalAutores:Arencibia M., Cabrera L., Carmen Elena Viada, Cepeda M., De La Torre A.V., Domecq M., Durán Y., Durrutí D., Fernandez L.E., Hernández J.J., Hernández L., Mabel Álvarez, Moreno Y.G., Pérez K., Ruiz R., Sánchez J.L., Sánchez L., Santiesteban E.R., Valls A.R., Vega A.M.Fuentes:scopus